11ÔÂ2ÈÕ£¬ÈÕ±¾ºñÉúÀͶ¯Ê¡£¨MHLW£©½â³ýÁËng28ÄϹ¬¿¹ñ²ðïÒ©INOVELON?Ƭ¼Á100mgºÍ200mg£¨Í¨ÓÃÃû£ºrufinamide£©×÷ΪÆäËû¿¹ñ²ðïÒ©ÎAED£©µÄ¸¨ÖúÁÆ·¨ÓÃÓÚÖÎÁÆÂ×ŵ¿Ë˹-¼Ó˹ÍÐ×ÛºÏÕ÷£¨LSG£©Åú¼þÖÐËùÐèµÄÉÏÊкóÊÓ²ìÐÔÑо¿£¬¼´È«°¸ÀýÑо¿µÄÒªÇó¡£
2013Äê3Ô£¬ÈÕ±¾ºñÉúÀͶ¯Ê¡Åú×¼ng28ÄϹ¬¿¹ñ²ðïÒ©INOVELON?×÷ΪÆäËû¿¹ñ²ðïÒ©ÎïµÄ¸¨ÖúÁÆ·¨£¬ÓÃÓÚÖÎÁÆÅãͬLSGµÄÇ¿Ö±ÐԺͷÇÇ¿Ö±ÐÔñ²ðﱬ·¢Ê±·¢Ã÷¸ÃÒ©Îï¶ÔÆäËû¿¹ñ²ðïÒ©ÎïµÄ·´Ó¦È±·¦¡ª¡ª¡°ÓÉÓÚÈÕ±¾ÁÙ´²ÊÔÑéÖÐÄÉÈëµÄÊÜÊÔÕßÊýÁ¿ºÜÊÇÓÐÏÞ£¬ÒªÇó¶Ô·þÓøÃÒ©Æ·µÄËùÓл¼Õß½øÐÐÉÏÊкóÊÓ²ìÐÔÑо¿£¬Ö±ÖÁÀÛ¼ÆÒ»¶¨ÃüÁ¿µÄ»¼ÕßÊý¾Ý£¬ÒÔ±ãʶ±ðʹÓøòúÆ·ÖÎÁÆ»¼ÕßµÄÅä¾°ÐÅÏ¢£¬ÊÕ¼¯¸Ã²úÆ·ÉÏÊкóÔçÆÚµÄÄþ¾²ÐÔºÍÓÐЧÐÔÊý¾Ý£¬´Ó¶ø½ÓÄÉÐëÒªµÄ²½·¥À´È·±£Ò©Æ·µÄÕýȷʹÓá£
×÷Ϊ¶ÔËùÓв¡ÀýÑо¿µÄÆÊÎö½á¹û£¬ng28ÄϹ¬Ìá½»ÁË702Ãû»¼ÕßµÄÄþ¾²ÐÔÊý¾ÝºÍ495Ãû»¼ÕßµÄÁÆЧÊý¾Ý¡£Æ¾¾ÝÌṩµÄÊý¾Ý£¬ºñÉúÀͶ¯Ê¡ÌåÏÖËùÓв¡ÀýµÄÑо¿½øÐÐÇ¡µ±£¬ÇÒ½ÓÄÉÁËÐëÒª²½·¥È·±£Ò©Æ·µÄÕýȷʹÓã¬Âú×ã½â³ýÌõ¼þ¡£
ng28ÄϹ¬½«¼ÌÐøŬÁ¦ÍƹãINOVELON?µÄÕýȷʹÓÃÒªÁì²¢Ìṩ¸ü¶àÓйزúÆ·µÄÐÅÏ¢£¬´Ó¶ø½øÒ»²½°ü¹Ü»¼Õß¼°Æä¼ÒÊôµÄÀûÒæ¡£
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120